natural pharmaceuticals derived From Cannabis and other medicinal plants
Company Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
Message: Tetra Bio-Pharma Accelerates Sales Strategy with the Appointment of Denis Courchesne as Vice President, Sales
OTTAWA, ONTARIO--(April 24, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP) (OTCQB:GRPOF), today announced that it has accelerated its sales strategy by entering into an employment agreement with Denis Courchesne as Vice President, Sales, effective Monday, May 1, 2017.
Mr. Courchesne has over 25 years' sales and management experience in the retail environment working for various companies such as Evian Spring Water (Danone) and Pfizer Canada.
In the last 15 years, he has been working in both the pharmacy and health food channels where he successfully held positions in Quebec as National Sales Manager. In his previous companies, he rapidly reorganized the sales forces enabling the teams to outperform their sales and profit objectives. Since 2010 Mr. Courchesne has been working as an independent consultant helping various brands in many aspects of their business such as marketing, strategy and goal establishment while enabling them to solidify their presence at store level.
"We are most pleased to welcome Mr. Courchesne to the team as we are focused on building Tetra as a leading bio-pharmaceutical organization," said Andre Rancourt, CEO of Tetra Bio-Pharma. "Mr. Courchesne has repeatedly demonstrated his skills as a natural leader that will allow Tetra to build our Agro Tek natural health division and drive strong revenue growth for the organization. The great relations he has successfully built over his career specifically in Canadian pharmacies will allow Tetra to accelerate placement of our products and ultimately drive stronger sales moving forward."
About Tetra Bio Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP) (OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange ("CSE") has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Vice President, IR & Corporate Communications
Please login to post a reply